Experimental Vein Graft Research: A Critical Appraisal of Models
DOI:
https://doi.org/10.17140/HROJ-2-110Keywords:
Coronary artery bypass graft, Percutaneous coronary intervention, Neointima, Arterialization, Anastomosis, OligodesoxynucleotideAbstract
Experimental models of vein grafting need to have specific relevance to the clinical
complications encountered in coronary artery bypass grafting: acute thrombosis, neointimaassociated
stenosis, and progression of late-forming atherosclerotic lesions. Despite extensive
use, many of these experimental models lack endpoint measures with clear analogies to their
clinical counterparts and may in fact target the wrong (patho) physiologic process. Model selection
is critical to further progress toward preventing these all too prevalent complications
used for heart revascularization.
References
Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Surgery: Executive Summary. Circulation. 2011; 124: 2610-2642. doi: 10.1161/ CIR.0b013e31823b5fee
Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan EL. Everolimus-eluting stents or bypass surgery for multives-selcoronary disease. N Engl J Med. 2015; 372:1213-1222. doi: 10.1056/NEJMoa1412168
Cohen DJ, Osnabrugge RL, Magnuson EA, et al. Cost-effec-tiveness of percutaneous coronary intervention with drug-elut-ing stents versus bypass surgery for patients with 3-vessel or left main coronary artery disease: final results from the synergy be-tween percutaneous coronary intervention with taxus and cardi-ac surgery (SYNTAX) trial. Circulation. 2014; 130: 1146-1157. doi: 10.1161/CIRCULATIONAHA.114.009985
Deb S, Wijeysundera HC, Ko DT, Tsubota H, Hill S, Fremes SE. Coronary artery bypass graft surgery vs percutaneous in-terventions in coronary revascularization: a systematic review. JAMA. 2013; 310: 2086-2095. doi: 10.1001/jama.2013.281718
Halabi AR, Alexander JH, Shaw LK, et al. Relation of early saphenous vein graft failure to outcomes following coronary ar-tery bypass surgery. Am J Cardiol. 2005; 96: 1254-1259. doi: 10.1016/j.amjcard.2005.06.067
Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circula-tion. 1998; 97:916-931. doi: 10.1161/01.CIR.97.9.916
Schachner T, Laufer G, Bonatti J. In vivo (animal) models of vein graft disease. European Journal of Cardio-thoracic Sur-gery. 2006; 30: 451-463. doi: 10.1016/j.ejcts.2006.06.015
Thomas AC. Animal models for studying vein graft failure and therapeutic interventions. Current Opinion in Pharmacol-ogy. 2012; 12: 121-126. doi: 10.1016/j.coph.2012.01.002
Yu P, Nguyen BT, Tao M, Campagna C, Ozaki CK. Ratio-nale and practical techniques for mouse models of early vein graft adaptations. J VascSurg. 2010; 52: 444-452. doi: 10.1016/j. jvs.2010.03.048
Cooney WP 3rd. Revascularization and replantation after up-per extremity trauma: experience with interposition artery and veingrafts. Clin Ortho Rel Res. 1978; 137: 227-234.
Khouri RK, Cooley BC, Kunselman AR, et al. A prospective study of microvascular free-flap surgery and outcome. Plast Re-constr Surg. 1998; 102: 711-721.
Yan H, Jackson WD, Songcharoen S, et al. Vein grafting in fingertip replantations. Microsurgery. 2009; 29: 275-281. doi: 10.1002/micr.20614
Pomerance J, Truppa K, John Bilos ZJ, Vender MI, Ruder JR, Sagerman SD. Replantation and revascularization of the dig-its in a community mictosurgical practice. J Reconstr Microsurg. 1997; 13: 163-170. doi: 10.1055/s-2007-1006400
Anand SX, Viles-Gonzalez JF, Mahboobi SK, Heerdt PM. Bivalirudin utilization in cardiac surgery: shifting anticoagula-tion from indirect to direct thrombin inhibition. Can J Anesth. 2011; 58: 296-311. doi: 10.1007/s12630-010-9423-0
Koster A, Chew D, Grundel M, et al. Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardio-pulmonary bypass. Anesth Analg. 2003; 96: 383-386.
Chesebro JH, Clements IP, Fuster V, et al. A platelet-inhib-itor-drug trial in coronary-artery bypass operations. Benefit of perioperative dipyridamole and aspirin therapy on early postop-erative vein-graft patency. N Engl J Med. 1982; 307: 73-78. doi: 10.1056/NEJM198207083070201
Rosa M, Lie JT, Bianco RL, Kaye MP. Reduction of thrombo-sis in canine coronary bypass vein grafts with dipyridamole and aspirin. Am J Cardiol. 1981; 47: 1248-1254. doi: 10.1016/0002- 9149(81)90254-X
Mannacio VA, Di Tommaso L, Antignan A, DeAmicis V, Vosa C. Aspirin plus clopidogrel for optimal plateletinhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary artery bypass occlusion after off-pump procedures) randomised study. Heart. 2012; 98: 1710-1715. doi: 10.1136/heartjnl-2012-302449
Gottlob R. The preservation of the venous endothelium by ‘dissection without touching’ and by an atraumatic technique of vascular anastomosis. The importance for arterial and venous surgery. Minerva Chir. 1977; 32: 693-700.
Adcock OT, Adcock GL, Wheeler JR, Gregory RT, Snyder SO, Gayle RG. Optimal techniques for harvesting and prepara-tion of reversed autogenous vein grafts for use as arterial substi-tutes: a review. Surgery. 1984; 96: 886-894.
Tsui JCS, Souza DSR, Filbey D, Bomfim V, Dashwood MR. Preserved endothelial integrity and nitric oxide synthase in saphenous vein grafts harvested by a ‘no-touch’ technique. Brit J Surg. 2001; 88: 1209-1215. doi: 10.1046/j.0007-1323- .2001.01855.x
Lumsden AB, Eaves FF III, Ofenloch JC, Jordan WD. Sub-cutaneous, video-assisted saphenous vein harvest: report of the first 30 cases. Cardiovasc Surg. 1996; 4: 771-776. doi: 10.1016/ s0967-2109(96)00055-5
Allen KB, Griffith GL, Heimansohn DA, et al. Endoscopic versus traditional saphenous vein harvesting: a prospective, ran-domized trial. Ann Thorac Surg. 1998; 66: 26-31. doi: 10.1016/ S0003-4975(98)00392-0
Williams JB, Peterson ED, Brennan JM, et al. Association between endoscopic vs. open vein-graft harvesting and mortal-ity, wound complications, and cardiovascular events in patients undergoing CABG surgery. JAMA. 2012; 308: 473-484. doi: 10.1001/jama.2012.8363
Ehsan A, Mann MJ, Dell’Acqua G, Tamura K, Braun-Dul-laeus R, Dzau VJ. Endothelial healing in vein grafts: prolifera-tive burst unimpaired by genetic therapy of neointimal disease. Circulation. 2002; 105: 1686-1692.
Cooley BC. Murine model of neointimal formation and stenosis in vein grafts. Arterioscler Thromb Vasc Biol. 2004; 24: 1180-1185. doi: 10.1161/01.ATV.0000129330.19057.9f
Mann MJ, Gibbons GH, Kernoff RS, et al. Genetic engineer-ing of vein grafts resistant to atherosclerosis. Proc Natl AcadSci U S A. 1995; 92: 4502-4506.
Mann MJ, Gibbons GH, Tsao PS, et al. Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts. J Clin Invest. 1997; 99: 1295-1301. doi: 10.1172/ JCI119288
Ehsan A, Mann MJ, Dell’Acqua G, Dzau VJ. Long-term stabilization of vein graft wall architecture and prolonged re-sistance to experimental atherosclerosis after E2F decoy oligo-nucleotide gene therapy. J ThoracCardiovascSurg. 2001; 121: 714-722. doi: 10.1067/mtc.2001.111204
Alexander JH, Hafley G, Harrington RA, et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery by-pass graft surgery. JAMA. 2005; 294: 2446-2454. doi: 10.1001/ hama.294.19.2446
Lopes RD, Williams JB, Mehta RH, et al. Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoj-ect of Ex-vivo Vein graft ENgineering via Transfection IV (PRE-VENT IV) 5-year results. Am Heart J. 2012; 164: 379.e1-386. e1. doi: 10.1016/j.ahj.2012.05.019
Cai X, Freedman NJ. New therapeutic possibilities for vein graft disease in the post-edifoligide era. Future Cardiol. 2006; 2: 493-501. doi: 10.2217/14796678.2.4.493
Lopes RD, Mehta RH, Hafley GE, et al. Relationship be-tween vein graft failure and subsequent clinical outcomes after coronary artery b ypass surgery. Circulation. 2012; 125: 749- 756. doi: 10.1161/CIRCULATIONAHA.111.040311
Mannion JD, Ormont ML, Magno MG, O’Brien JE, Shi Y, Zalewski A. Sustained reduction of neointima with c-myc antisense oligonucleotides in saphenous vein grafts. Ann Tho-rac Surg. 1998; 66: 1948-1952. doi: 10.1016/S0003-4975- (98)01168-0
Mehta D, George SJ, Jeremy JY, et al. External stenting re-duces long-term medial and neointimal thickening and platelet derived growth factor expression in a pig model of arteriovenous bypass grafting. Nat Med. 1998; 4: 235-239. doi: 10.1038/ nm0298-235
Rittgers SE, Karayannacos PE, Guy JF, et al. Velocity dis-tribution and intimal proliferation in autologous vein grafts in dogs. Circ Res. 1978; 42: 792-801.
Keynton RS, Evancho MM, Sims RL, Rodway NV, Gobin A, Rittgers SE. Intimal hyperplasia and wall shear in arterial bypass graft distal anastomoses: an in vivo model study. J BiomechEng. 2001; 123: 464-473. doi: 10.1115/1.1389461
Zilla P, Moodley L, Scherman J, et al. Remodeling leads to distinctly more intimal hyperplasia in coronary than in in-frainguinal vein grafts. J VascSurg. 2012; 55: 1734-1741. doi: 10.1016/j.jvs.2011.11.057
Abbasi K, Shalileh K, Anvari MS, et al. Perivascular nitric oxide delivery to saphenous vein grafts prevents graft stenosis after coronary artery bypass grafting: a novel sheep model. Car-diol. 2011; 118: 8-15. doi: 10.1159/000324316
Shiroma H, Kusaba A. Ultrastructural features of progressive intimal hyperplasia at the distal end-to-side anastomosis of vein grafts. Cardiovasc Surg. 1996; 4: 393-398. doi: 10.1016/0967- 2109(95)00081-X
Saito T, Iguchi A, Tabayashi K. Irradiation inhibits vascular anastomotic stenosis in a canine model. Gen Thorac Cardiovasc Surg. 2009; 57: 406-412. doi: 10.1007/s11748-009-0413-5
Zou Y, Dietrich H, Hu Y, Metzler B, Wick G, Xu Q. Mouse model of venous bypass graft arteriosclerosis. Am J Pathol. 1998; 153: 1301-1310. doi: 10.1016/S0002-9440(10)65675-1
Zhang L, Hagen PO, Kisslo J, Peppel K, Freedman NJ. Neointimal hyperplasia rapidly reaches steady state in a nov-el murine vein graft model. J VascSurg. 2002; 36: 824-832. doi: 10.1067/mva.2002.126308
Diao Y, Xue J, Segal MS. A novel mouse model of autolo-gous venous graft intimal hyperplasia. J Surg Res. 2005; 126: 106-113. doi: 10.1016/j.jss.2005.01.025
Salzberg SP, Filsoufi F, Anyanwu A, et al. Increased neointi-mal formation after surgical vein grafting in a murine model of type 2 diabetes. Circulation. 2006; 114: I302-1307. doi: 10.1161/ CIRCULATIONAHA.105.001339
Shi C, Patel A, Zhang D, et al. Plasminogen is not required for neointima formation in a mouse model of vein graft stenosis. Circ Res. 1999; 84: 883-890. doi: 10.1161/01.RES.84.8.883
Sakaguchi T, Asai T, Belov D, et al. Influence of ischemic injury on vein graft remodeling: role of cyclic adenosine mono-phosphate second messenger pathway in enhanced vein graft preservation. J ThoracCardiovascSurg. 2005; 129: 129-137. doi: 10.1016/j.jtcvs.2004.04.014
Cooley BC, Nevado J, Mellad J, et al. TGF-β signaling medi-ates endothelial to mesenchymal transition (EndMT) during vein graft remodeling. Science Translat Med. 2014; 6: 227ra234. doi: 10.1126/scitranslmed.3006927
Cooley BC. Differential neointimal response in vein grafts and wire-injured arteries. Circ J. 2007; 71:1 649-1652. doi: 10.1253/circj.71.1649
Lytle BW, Loop FD, Taylor PC, et al. Vein graft disease: the clinical impact of stenoses in saphenous vein bypass grafts to coronary arteries. J ThoracCardiovascSurg. 1992; 103: 831- 840.
Leitges M, Mayr M, Braun U, et al. Exacerbated vein graft arteriosclerosis in protein kinase Cdelta-null mice. J Clin Invest. 2001; 108: 1505-1512. doi: 10.1172/JCI12902
Hu Y, Mayr M, Metzler B, Erdel M, Davison F, Xu Q. Both donor and recipient origins of smooth muscle cells in vein-graft atherosclerotic lesions. Circ Res. 2002; 91: e13-e20. doi: 10.1161/01.RES.0000037090.34760.EE
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Heart Research (HROJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.